학술논문

Glecaprevir–pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies—a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2)
Document Type
Article
Source
In The Lancet Gastroenterology & Hepatology September 2020 5(9):839-849
Subject
Primary Research
Articles
Language
ISSN
2468-1253